Crossref
COVID-19 Update: Metformin to Prevent Long Covid?
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1677e ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Metformin, COVID-19.
Abstract (Originalsprache)
Results from a double-blind trial suggest that off-label use of the oral antihyperglycemic drug metformin in patients with COVID-19 may decrease the risk of post-acute sequelae of SARS-CoV-2 infection (“long COVID”).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
MetforminCOVID-19HumansPost-Acute COVID-19 SyndromeHypoglycemic AgentsSARS-CoV-2Ivermectin
Stichwörter der Autor:innen
COVID-19adverse effectsdosagedrug interactionsefficacyfluvoxamineivermectinmetforminsafety
Substanzen
MetforminHypoglycemic AgentsIvermectin
Zitieren
APA
(2023). COVID-19 Update: Metformin to Prevent Long Covid?. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1677e
Vancouver
COVID-19 Update: Metformin to Prevent Long Covid?. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1677e
BibTeX
@article{euvimed2023,
title = {COVID-19 Update: Metformin to Prevent Long Covid?},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1677e}
}
EUVIMED